March 11, 2013 at 08:20 AM EDT
FDA Programs Designed to Speed Up Approval Process Helps Send Drug Approvals to a 15-Year High in 2012
Five Star Equities Provides Stock Research on Aegerion Pharmaceuticals and Alnylam

NEW YORK, NY -- (Marketwire) -- 03/11/13 -- Programs developed by the U.S. Food and Drug Administration to speed up the approval process has been a major driver for growth within the Biotech Industry. In 2012, FDA drug approvals totaled a 15-year high of 39, over the past decade drug approvals has averaged roughly 23 a year, according to a recent Bloomberg article. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY).

Access to the full company reports can be found at:

www.FiveStarEquities.com/AEGR

www.FiveStarEquities.com/ALNY

The FDA's new "breakthrough" product designation allows new drugs to win approval after just a single round of testing, instead of the usual three. A total of three promising experimental medicines have been assigned the new status so far, while an additional 18 drugs have applied. The new designation follows three other programs -- Fast Track, Priority Review and Accelerated Approval -- each of which were designed to help bring crucial new drugs to market in a shorter amount of time.

"A breakthrough drug is one that may offer important new benefits for patients with serious or life-threatening disease who are especially in need of new safe and effective treatments," said Janet Woodcock, director of FDA's Center for Drug Evaluation and Research.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Aegerion Pharmaceuticals plans to conduct clinical development activities to support a marketing authorization application for lomitapide in HoFH in Japan and in support their planned clinical study of lomitapide in pediatric and adolescent HoFH patients. For fiscal year 2013, the company expects net revenues to be in the range of $15 million to $20 million.

Alnylam is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis, ALN-AT3 for the treatment of hemophilia and rare bleeding disorders, ALN-AS1 for the treatment of acute intermittent porphyria, ALN-PCS for the treatment of hypercholesterolemia, and ALN-TMP for the treatment of hemoglobinopathies.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

www.FiveStarEquities.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here